Philippa Flint

Philippa Flint has more than 11 years of experience in drug development and regulatory affairs at big pharma, combined with 10 years of capital markets experience as an equity research analyst. Prior to becoming Princial of Private Debt at CPP Investment Board she was working at Bloom Burton & Co. Flint and previously was an equity analyst at RBC Dominion Securities, providing research coverage of small- to mid-cap biotech/pharma companies. She has been consistently ranked the top earnings estimator in Canada in the healthcare sector by StarMine, including over the period from 2004-2008 and in 2011. Prior to this, Flint was the vice president for medical affairs at AstraZeneca Canada, managing a department of 150 people working on more than 100 clinical trials. She led the merger of Astra and Zeneca in Canada, prior to which she was the vice president for regulatory affairs and corporate project management at Astra Canada. Flint holds master's of science degree and a master's degree in business administration.
Recent Quotes
"ONCY's phase 3 head and neck cancer data are still on the horizon."
—
Philippa Flint, Bloom Burton & Co.
(10/1/13)
more >
"ONCY's phase 3 head and neck survival data are expected in H2/13."
—
Philippa Flint, Bloom Burton & Co.
(5/9/13)
more >
"We expect data this year on the key studies for ONCY's Reolysin."
—
Philippa Flint, Bloom Burton & Co.
(3/20/13)
more >
"We expect OGXI's shares to gain in value in H2/13."
—
Philippa Flint, Bloom Burton & Co.
(3/8/13)
more >
"ONCY has successfully raised at least 12 months' additional cash.'
—
Philippa Flint, Bloom Burton & Co.
(2/20/13)
more >
"In phase 2, ONCY showed 95% of patients had some tumor shrinkage."
—
Philippa Flint, Bloom Burton & Co.
(2/8/13)
more >
"We are encouraged by ONC's early Reolysin data."
—
Philippa Flint, Bloom Burton & Co.
(12/18/12)
more >
"We maintain our Buy rating on ONC given potential upside."
—
Philippa Flint, Bloom Burton & Co.
(9/12/12)
more >